Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification
Study phase (if other): I/II
Primary disease category: Cancer
Sponsor: Joanne Jeter
Projected enrollment dates: November 2016 to November 2022
Official study title: phase 1/2 trial of Pembrolizumab in combination with Imatinib in patients with locally advanced or metastatic melanoma with c-KIT mutation or amplification.
ClinicalTrials.gov page:
http://www.clinicaltrials.gov/show/NCT02812693